The Pharma Data

JANUARY 14, 2021

PRA Health Sciences selected for the study which will position Awakn at the Forefront of Psychedelic Research for Addiction Treatment. While there are current treatment methods available, which are effective for some segments of the population, relapse rates are high. To learn more about PRA, please visit www.prahs.com.

Science 52

Science Treatment Clinical Trials Clinical Development 52

The Pharma Data

APRIL 27, 2022

We plan to discuss these data with health authorities, and we will continue to expand our tislelizumab clinical development program in pursuit of novel, synergistic combinations with the ultimate goal of extending survival for more patients.”. About 108,000 people of more than 140 nationalities work at Novartis around the world.

Treatment 52

Treatment Clinical Development Therapies Clinical Trials 52

The Pharma Data

JANUARY 17, 2021

“Our internal cell therapy process expertise combined with Lonza’s cell processing know-how provide the perfect combination to manufacture ARU-1801 for our pivotal study. As we advance our gene therapy through clinical trials, this partnership signifies a critical milestone in the development pathway.”

Disease 52

Disease Trials Treatment Clinical Trials 52

The Pharma Data

AUGUST 19, 2021

Oral presentation at the International Association for the Study of Lung Cancer’s (IASLC) 2021 World Conference on Lung Cancer (WCLC) shows evidence that the bispecific mechanism of action for RYBREVANT TM can provide anti-tumor activity against either EGFR-mutated or MET-mutated non-small cell lung cancer. 1 Treatment-related Grade ?3

Treatment 52

Treatment FDA Approval Pharmacokinetics FDA 52

The Pharma Data

OCTOBER 14, 2020

a clinical-stage biopharmaceutical company focused on discovering and developing a new generation of antibody therapeutics for oncology, announced today that the U.S. SAN CARLOS, Calif. , 15, 2020 /PRNewswire/ — Apexigen, Inc. , Binding of APX005M to CD40 on antigen presenting cells (i.e.,

Treatment 40

Treatment Immune Response Clinical Trials Clinical Development 40

The Pharma Data

AUGUST 15, 2021

Vivet Therapeutics (“Vivet”), a clinical-stage biotechnology company, and Pfizer Inc. Vivet Therapeutics is a clinical-stage emerging biotechnology company developing novel gene therapy treatments for rare, inherited metabolic diseases. Vivet’s lead program, VTX-801, is currently under clinical development.

Disease 52

Disease FDA Treatment Clinical Trials 52

The Pharma Data

JANUARY 27, 2021

HK), announced today that China Center for Drug Evaluation (CDE) has granted Breakthrough Therapy designation to Batoclimab (HBM 9161), a fully human anti-FcRn monoclonal antibody (mAb), for the treatment of adult patients with Myasthenia Gravis (MG). CAMBRIDGE, Mass. ROTTERDAM, Netherlands and SUZHOU, China , Jan. ” he added.

Therapies 40

Therapies Treatment International Licensing 40

The Pharma Data

MARCH 9, 2021

New data from 10 studies will be presented by Eli Lilly and Company (NYSE: LLY) at the upcoming virtual International Conference on Alzheimer’s & Parkinson Diseases 2021 (AD/PD 2021), March 9-14, 2021. vice president of Alzheimer’s disease development unit, Eli Lilly and Company. Mevidalen/D1PAMs.

Disease 40

Disease International Research Therapies 40

The Pharma Data

NOVEMBER 3, 2020

Food and Drug Administration (FDA) has granted Fast Track designation to its clinical candidate, LB-001 for the treatment methylmalonic acidemia (MMA). Top-tier capsid candidates from this effort demonstrated significant improvements over benchmark AAVs currently in clinical development.

FDA 40

FDA Treatment Clinical Trials Clinical Development 40

The Pharma Data

DECEMBER 29, 2020

(NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx ® plant cell-based protein expression system, and Chiesi Global Rare Diseases , a business unit of Chiesi Farmaceutici S.p.A.,

Clinical Trials 52

Clinical Trials Disease Treatment Trials 52

The Pharma Data

NOVEMBER 25, 2020

26, 2020 /PRNewswire/ — Cantargia AB (OMXS: CANTA) and BioInvent International AB (OMXS: BINV), today announced that BioInvent has been contracted as manufacturer of Cantargia’s antibody CAN10 in preclinical development for the treatment of systemic sclerosis and myocarditis. LUND, Sweden , Nov. About BioInvent.

Clinical Trials 52

Clinical Trials Licensing Licensing International 52

Metabolite Tales Blog

NOVEMBER 17, 2022

Due to internal hydrogen bonding, DELAQ is a linear, nonionized metabolite with a LogP of roughly 7. Figure 2: Internal hydrogen bonding of DELAQ In contrast to laquinimod, DELAQ is a very potent activator of the aryl hydrocarbon receptor (AhR). and a topological polar surface area (TPSA) of 61 Å 2.

International 52

International Licensing Licensing Treatment 52

The Pharma Data

SEPTEMBER 6, 2021

The primary efficacy outcome was met showing a statistically significant reduction in the 24-hour cough count (average hourly cough frequency based on 24-hour sound recordings) of up to 27% for eliapixant 75 mg twice daily over placebo after 12 weeks of treatment. About the Phase IIb Study. About the Phase IIb Study.

Trials 52

Trials Clinical Trials Treatment International 52

The Pharma Data

JANUARY 6, 2021

7, 2021 /PRNewswire/ — UNION therapeutics A/S ( UNION ) today announces that the US Food and Drug Administration (FDA) has approved an Investigational New Drug program (IND) for oral orismilast; a next generation PDE4-inhibitor for the treatment of plaque psoriasis in adults. One step closer to a novel treatment.

FDA Approval 52

FDA Approval FDA Clinical Development Clinical Research 52

The Pharma Data

JANUARY 20, 2021

In order to do so, the DSMC may review unblinded study information (on a patient level or treatment group level) during the conduct of the trial. Dr. Rouleau has an international reputation in cardiovascular research, particularly in the field of both basic mechanisms and improving the clinical care of patients with heart failure.

Hospitals 52

Hospitals Trials International Clinical Trials 52

Advarra

OCTOBER 15, 2024

The International Council for Harmonisation (ICH) good clinical practice (GCP) guidelines are critical in ensuring the safety and rights of clinical trial participants. Sponsors should ensure a diverse multidisciplinary team of stakeholders supports the design of the study and the clinical development plan.

Clinical Trials 52

Clinical Trials Trials Clinical Research International 52

The Pharma Data

NOVEMBER 10, 2020

Growing into a biopharmaceutical company, Innovent has built an integrated platform covering from drug discovery, CMC, clinical development and commercialization. By joining Innovent, Dr. Liu will be responsible for global R & D, pipeline strategy, business development and international operations.

Biosimilars 52

Biosimilars Clinical Trials International Clinical Development 52

The Pharma Data

JULY 29, 2021

Eisai and Biogen Present Preliminary Assessment of the Clinical Effects of Lecanemab Following 18 Months of Treatment in the Open-Label Extension of the Phase 2 Proof of Concept Study at 2021 Alzheimer’s Association International Conference (AAIC) . 42/40 ratio, brain amyloid by PET and treatment Low values of plasma A?42/40

Clinical Trials 52

Clinical Trials Treatment Clinical Development Disease 52

The Pharma Data

JANUARY 27, 2021

“The responses observed in six out of nine patients are very encouraging and clearly suggest that BI-1206 may restore the response to rituximab in patients who have few treatment alternatives. ET ) to discuss the results and next steps in clinical development of BI-1206. (Nasdaq: CASI), a U.S.

Pharmaceuticals 52

Pharmaceuticals Clinical Trials Licensing Licensing 52

Drug Target Review

OCTOBER 1, 2024

Indeed, I’m afraid to say I experienced some biases regarding my lack of experience when I joined my first company, especially from non-medical colleagues who saw me as an internal competitor. The possibility of using new technologies to build new, more effective and less toxic therapies has opened new horizons for the treatment of cancer.

Doctors 97

Doctors Therapies Science Pharma Companies 97

The Pharma Data

JANUARY 13, 2021

This is our sixth global approval for an internally-developed product, and our first approval for tislelizumab in a lung cancer indication, an area where we believe tislelizumab can have a large impact for patients.”. This is the third approval in China for tislelizumab, and its first in a lung cancer indication.

Production 52

Production Trials Clinical Trials Treatment 52

The Pharma Data

JANUARY 14, 2021

We are strongly encouraged by these data and the potential for a frontline targeted treatment that can improve overall survival,” said Zev A. Associate Professor of Medicine at UCLA, Co-director of the Gastrointestinal Oncology Program and Director of Early Phase Clinical Research at the Jonsson Comprehensive Cancer Center.

Trials 52

Trials Treatment Therapies Clinical Trials 52

The Pharma Data

OCTOBER 18, 2020

DUBLIN–( BUSINESS WIRE )– Inflection Biosciences Ltd , a company developing innovative therapeutics for the treatment of cancer, today announced the appointment of industry veteran Gregory I. Dr. Berk most recently has served as a consultant to several companies developing oncology therapies. 19, 2020 08:02 UTC.

Small Molecule 40

Small Molecule Clinical Development Clinical Trials Licensing 40

The Pharma Data

DECEMBER 8, 2020

9, 2020 /PRNewswire/ — The members of the Nomination Committee for BioInvent International AB :s (publ) (“BioInvent) Annual General Meeting in 2021 have now been appointed. Proposals to the Nomination Committee can be sent to Stefan Ericsson , by mail: BioInvent International AB (publ).), BioInvent International AB (publ).

Clinical Trials 40

Clinical Trials Licensing Licensing International 40

The Pharma Data

OCTOBER 26, 2020

The conference call dial-in numbers are (844) 815-2882 for domestic callers and (213) 660-0926 for international callers. Synlogic’s proprietary pipeline includes Synthetic Biotics for the treatment of metabolic disorders including Phenylketonuria (PKU) and Enteric Hyperoxaluria (HOX).

Clinical Trials 52

Clinical Trials Clinical Development Trials Engineering 52

The Pharma Data

OCTOBER 15, 2020

ASLAN believes ASLAN003 has the potential to bethe most potent oral inhibitor of DHODH currently in development for autoimmune disease, more than 30 times more potent at inhibiting the DHODH enzyme than teriflunomide. SINGAPORE, Oct. SINGAPORE, Oct. The company expects to share further details in early 2021.

Pharmaceuticals 40

Pharmaceuticals Cell Based Assays Clinical Development Treatment 40

The Pharma Data

DECEMBER 13, 2020

” FORTRESS (POL6326-009) is an international, multicenter, randomized active-controlled, open-label Phase III trial which will investigate the efficacy, safety and tolerability of intravenous balixafortide given with eribulin versus eribulin alone in the treatment of HER2 negative, locally recurrent or metastatic breast cancer.

Clinical Trials 52

Clinical Trials Trials Clinical Development Treatment 52

The Pharma Data

APRIL 6, 2022

Novartis will integrate the Pharmaceuticals and Oncology business units and create two separate commercial organizations with a stronger geographic focus – Innovative Medicines US and Innovative Medicines International. About 109,000 people of more than 140 nationalities work at Novartis around the world.

International 52

International Pharmaceuticals Drug Development Marketing 52

The Pharma Data

NOVEMBER 10, 2020

The NCT03763149 study is a phase 1a clinical study evaluating the tolerability, safety, and PK/PD properties of IBI188 (letaplimab) as monotherapy for advanced malignancies that failed in standard treatments. . . SAN FRANCISCO , U.S. and SUZHOU, China , Nov. ” About Letaplimab.

Clinical Trials 52

Clinical Trials Treatment Trials Disease 52

The Pharma Data

AUGUST 11, 2020

development lead, Gastrointestinal Cancers, Bristol Myers Squibb. “We We look forward to engaging health authorities worldwide with the goal of bringing this immunotherapy-based treatment option to patients as soon as possible.”. Waxman, M.D., While GEJ cancer has a lower prevalence than gastric cancer, it continues to rise.

Treatment 52

Treatment Trials Therapies Clinical Trials 52

The Pharma Data

OCTOBER 14, 2020

Food and Drug Administration (FDA) has approved WAKIX® (pitolisant) for the treatment of cataplexy in adult patients with narcolepsy. WAKIX is the first and only treatment approved by the FDA for people with excessive daytime sleepiness or cataplexy associated with narcolepsy that is not scheduled as a controlled substance by the U.S.

FDA Approval 40

FDA Approval FDA Treatment Clinical Trials 40

The Pharma Data

JANUARY 19, 2021

The event will feature a presentation by renowned lymphoma expert Mats Jerkeman, MD, Lund University, who will discuss the current treatment landscape, and unmet medical need for patients with relapsed or refractory Non-Hodgkin’s Lymphoma for whom current treatment options are very limited. LUND, Sweden , Jan. About BioInvent.

Clinical Trials 40

Clinical Trials Licensing Licensing International 40

LifeSciVC

OCTOBER 18, 2023

As we think about our own future with our Phase 2 ready program, we discuss internally how well we fit venture funds’ criteria today and just what is an ’ideal‘ investment profile in 2023 going into 2024? And, of course, asthma and COPD patients are quite familiar with the approach of inhalation as part of their daily treatment regimen.

Clinical Development 61

Clinical Development Clinical Trials Marketing Production 61

The Pharma Data

DECEMBER 28, 2020

Her international experience in leading clinical development and in building development organizations will significantly strengthen our clinical capacity. This is crucial in the phase we are in now, with two products on the way to Phase II and another product in clinical Phase I.

Clinical Development 40

Clinical Development Drug Development Doctors International 40

The Pharma Data

NOVEMBER 30, 2020

Toll Free) or +1-412-317-6671 (International) and entering replay pin number: 13713850. Tiziana Life Sciences plc is a UK biotechnology company that focuses on the discovery and development of novel molecules to treat human disease in oncology and immunology. About Tiziana Life Sciences. +44 (0)20 7495 2379.

Science 40

Science Clinical Trials Disease Clinical Development 40

The Pharma Data

OCTOBER 27, 2020

Clynes developed several novel therapeutic approaches in cancer and autoimmunity, including DC targeting for cancer vaccines and Syk and JAK mediated inhibition of DCs and T cells in autoimmunity therapy. He is an internationally recognized key opinion leader, clinical investigator and translational research in mesothelioma.

Virus 40

Virus Clinical Development Engineering International 40

The Premier Consulting Blog

JULY 9, 2023

Food and Drug Administration (FDA), expect identification, reporting, and qualification of these compounds according to three key guidance documents established by the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). Global regulatory agencies, including the U.S.

Small Molecule 52

Small Molecule DNA Drugs Clinical Development 52